Published in Clin Infect Dis on June 15, 2008
Study of the Complications Associated With Certain Stem Cell Transplants | NCT01919099
Anidulafungin in Patients With Hematologic Malignancies (ECALTA) | NCT01053884
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant (2009) 5.10
Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis (2010) 3.26
The serum galactomannan index predicts mortality in hematopoietic stem cell transplant recipients with invasive aspergillosis. Clin Infect Dis (2013) 3.15
Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis (2011) 2.84
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2012) 2.45
Histopathologic diagnosis of fungal infections in the 21st century. Clin Microbiol Rev (2011) 2.27
Aspergillus PCR: one step closer to standardization. J Clin Microbiol (2010) 2.23
Common severe infections in chronic granulomatous disease. Clin Infect Dis (2014) 2.10
Current knowledge of Trichosporon spp. and Trichosporonosis. Clin Microbiol Rev (2011) 2.08
Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother (2012) 2.05
Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients. Clin Infect Dis (2014) 2.03
Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. J Infect (2011) 1.90
Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species. Clin Microbiol Rev (2011) 1.82
High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis (2011) 1.72
Epidemiology of cryptococcal meningitis in the US: 1997-2009. PLoS One (2013) 1.69
Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother (2012) 1.67
Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. Emerg Infect Dis (2015) 1.61
Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis (2010) 1.60
PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol (2010) 1.59
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis (2016) 1.58
Clostridium difficile infection after adult autologous stem cell transplantation: a multicenter study of epidemiology and risk factors. Biol Blood Marrow Transplant (2013) 1.58
Invasive mold infections following combat-related injuries. Clin Infect Dis (2012) 1.55
Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis (2012) 1.55
Acute myeloid leukaemia: challenges and real world data from India. Br J Haematol (2015) 1.51
The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis (2011) 1.49
Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant (2012) 1.44
Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J Clin Microbiol (2010) 1.43
Galactomannan Testing and the Incidence of Invasive Pulmonary Aspergillosis: A 10-Year Nationwide Population-Based Study in Taiwan. PLoS One (2016) 1.42
Contribution of Candida biomarkers and DNA detection for the diagnosis of invasive candidiasis in ICU patients with severe abdominal conditions. Crit Care (2016) 1.41
Molecular methods to improve diagnosis and identification of mucormycosis. J Clin Microbiol (2011) 1.41
Detection of a Serum Siderophore by LC-MS/MS as a Potential Biomarker of Invasive Aspergillosis. PLoS One (2016) 1.40
Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother (2012) 1.39
Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1→3)-β-D-glucan assay, Candida score, and colonization index. Crit Care (2011) 1.38
Multiplex blood PCR in combination with blood cultures for improvement of microbiological documentation of infection in febrile neutropenia. J Clin Microbiol (2010) 1.38
Tracheobronchial manifestations of Aspergillus infections. ScientificWorldJournal (2011) 1.37
International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother (2010) 1.35
Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant (2009) 1.34
Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother (2009) 1.34
Detection of a molecular biomarker for zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage, and lung tissue in a rabbit model of experimental pulmonary zygomycosis. J Clin Microbiol (2008) 1.33
Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Korean J Intern Med (2011) 1.32
Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine (Baltimore) (2012) 1.31
Magnetic resonance imaging of pulmonary infection in immunocompromised children: comparison with multidetector computed tomography. Pediatr Radiol (2016) 1.31
In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study. J Clin Microbiol (2012) 1.28
Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patients. J Clin Microbiol (2011) 1.28
Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. Crit Care (2015) 1.28
Serum (1-3)-beta-D-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J Clin Microbiol (2009) 1.27
Galactomannan testing for early diagnosis of Exserohilum rostratum infection. J Clin Microbiol (2013) 1.24
PCR-based diagnosis of human fungal infections. Expert Rev Anti Infect Ther (2009) 1.24
The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project. Haematologica (2011) 1.23
Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis. J Clin Microbiol (2012) 1.23
Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study). Antimicrob Agents Chemother (2013) 1.22
Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother (2009) 1.21
Cross-reactivity of Fusarium spp. in the Aspergillus Galactomannan enzyme-linked immunosorbent assay. J Clin Microbiol (2012) 1.20
Granulocyte transfusions in severe aplastic anemia: an eleven-year experience. Haematologica (2009) 1.20
Epidemiology and treatment approaches in management of invasive fungal infections. Clin Epidemiol (2011) 1.20
Evaluation of analytical and preliminary clinical performance of Myconostica MycAssay Aspergillus when testing serum specimens for diagnosis of invasive Aspergillosis. J Clin Microbiol (2011) 1.20
Critical stages of extracting DNA from Aspergillus fumigatus in whole-blood specimens. J Clin Microbiol (2010) 1.20
Emerging fungal infections in immunocompromised patients. F1000 Med Rep (2011) 1.18
Diagnostic accuracy of serum 1,3-β-D-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol (2011) 1.18
Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience. Haematologica (2011) 1.17
Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica (2011) 1.17
The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care (2010) 1.17
Significant decline in Galactomannan Signal during storage of clinical serum samples. Int J Mol Sci (2013) 1.16
Diagnosis of invasive aspergillosis by a commercial real-time PCR assay for Aspergillus DNA in bronchoalveolar lavage fluid samples from high-risk patients compared to a galactomannan enzyme immunoassay. J Clin Microbiol (2011) 1.15
Infections in liver transplant recipients. World J Hepatol (2011) 1.14
Trichosporon mycotoxinivorans, a novel respiratory pathogen in patients with cystic fibrosis. J Clin Microbiol (2009) 1.14
Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome. Scientifica (Cairo) (2013) 1.14
Increasing incidence of mucormycosis in University Hospital, Belgium. Emerg Infect Dis (2010) 1.13
Clinical features of invasive bronchial-pulmonary aspergillosis in critically ill patients with chronic obstructive respiratory diseases: a prospective study. Crit Care (2011) 1.13
Parainfluenza virus lower respiratory tract disease after hematopoietic cell transplant: viral detection in the lung predicts outcome. Clin Infect Dis (2014) 1.12
Evaluation of real-time PCR, galactomannan enzyme-linked immunosorbent assay (ELISA), and a novel lateral-flow device for diagnosis of invasive aspergillosis. J Clin Microbiol (2013) 1.12
Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother (2012) 1.11
Cutaneous Invasive Aspergillosis: Retrospective Multicenter Study of the French Invasive-Aspergillosis Registry and Literature Review. Medicine (Baltimore) (2015) 1.11
Intestinal damage determines the inflammatory response and early complications in patients receiving conditioning for a stem cell transplantation. PLoS One (2010) 1.11
Correlation of clinical outcomes with β-glucan levels in patients with invasive candidiasis. J Clin Microbiol (2012) 1.10
Aspergillus niger: an unusual cause of invasive pulmonary aspergillosis. J Med Microbiol (2010) 1.09
First detection of TR46/Y121F/T289A and TR34/L98H alterations in Aspergillus fumigatus isolates from azole-naive patients in Denmark despite negative findings in the environment. Antimicrob Agents Chemother (2014) 1.09
Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011. Antimicrob Agents Chemother (2013) 1.09
Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis. PLoS One (2012) 1.09
Fungal infections in intensive care unit: challenges in diagnosis and management. Ann Med Health Sci Res (2013) 1.09
Multicenter, prospective clinical evaluation of respiratory samples from subjects at risk for Pneumocystis jirovecii infection by use of a commercial real-time PCR assay. J Clin Microbiol (2011) 1.08
Is azole resistance in Aspergillus fumigatus a problem in Spain? Antimicrob Agents Chemother (2013) 1.08
Galactomannan testing of bronchoalveolar lavage fluid is useful for diagnosis of invasive pulmonary aspergillosis in hematology patients. BMC Infect Dis (2010) 1.07
Anti-Aspergillus human host defence relies on type 1 T helper (Th1), rather than type 17 T helper (Th17), cellular immunity. Immunology (2009) 1.07
Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. BMC Infect Dis (2014) 1.07
Pulmonary aspergillosis: clinical presentation, diagnostic tests, management and complications. Curr Opin Pulm Med (2010) 1.06
Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and Echinocandin resistance. Antimicrob Agents Chemother (2013) 1.06
Role of NADPH oxidase versus neutrophil proteases in antimicrobial host defense. PLoS One (2011) 1.06
Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model. Antimicrob Agents Chemother (2015) 1.06
Reactivity of (1→3)-β-d-glucan assay in bacterial bloodstream infections. Eur J Clin Microbiol Infect Dis (2011) 1.05
Timeline, epidemiology, and risk factors for bacterial, fungal, and viral infections in children and adolescents after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2012) 1.05
Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006. J Antimicrob Chemother (2010) 1.05
Invasive fungal disease in autosomal-dominant hyper-IgE syndrome. J Allergy Clin Immunol (2010) 1.05
High Levels of beta-D-glucan in immunocompromised children with proven invasive fungal disease. Clin Vaccine Immunol (2010) 1.05
Validation and comparison of clinical prediction rules for invasive candidiasis in intensive care unit patients: a matched case-control study. Crit Care (2011) 1.04
Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother (2008) 1.04
Invasive fungal infections in patients with hematologic malignancies (aurora project): lights and shadows during 18-months surveillance. Int J Mol Sci (2012) 1.04
Multicenter comparison of serum and whole-blood specimens for detection of Aspergillus DNA in high-risk hematological patients. J Clin Microbiol (2013) 1.04
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med (2002) 17.04
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis (2001) 12.73
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med (2007) 10.40
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med (2004) 8.11
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med (2007) 7.91
Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med (2002) 7.85
Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis (2005) 5.24
Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis (2007) 5.15
Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) (2000) 4.98
Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis (2006) 4.42
Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis (2004) 4.15
Diagnosis of cryptococcal meningitis. Value of immunologic detection of cryptococcal antigen. N Engl J Med (1971) 4.07
Plasma (1-->3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet (1995) 3.64
Glossary of terms for CT of the lungs: recommendations of the Nomenclature Committee of the Fleischner Society. Radiology (1996) 3.39
Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis (2005) 3.31
Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis (2004) 2.98
Contribution of (1->3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol (2005) 2.38
Invasive aspergillosis in the intensive care unit. Clin Infect Dis (2007) 2.34
Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1-->3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol (2004) 2.28
Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis (2006) 2.21
The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol (2005) 2.21
Serologic studies in coccidioidomycosis. Semin Respir Infect (2001) 2.00
Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a ways to go. Clin Infect Dis (2006) 1.84
Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis (2007) 1.83
Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study. Clin Infect Dis (2005) 1.43
Usefulness of the MSG/IFICG/EORTC diagnostic criteria of invasive pulmonary aspergillosis in the clinical management of patients with acute leukaemia developing pulmonary infiltrates. Ann Hematol (2006) 1.39
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med (2008) 31.57
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med (2004) 24.47
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis (2009) 22.98
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant (2005) 19.83
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med (2002) 19.60
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis (2009) 18.19
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med (2002) 17.04
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51
Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS (2009) 16.37
Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis (2005) 13.97
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis (2010) 11.65
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med (2007) 10.40
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis (2011) 9.37
Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis (2005) 8.77
Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus. Nature (2005) 8.55
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med (2007) 8.33
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis (2002) 7.81
Sequencing of Aspergillus nidulans and comparative analysis with A. fumigatus and A. oryzae. Nature (2005) 7.74
Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet (2006) 7.33
Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med (2010) 7.20
Hidden killers: human fungal infections. Sci Transl Med (2012) 7.10
Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med (2012) 6.30
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis (2002) 6.13
Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med (2007) 5.88
Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis (2012) 5.83
Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis (2012) 5.66
Guidelines for treatment of candidiasis. Clin Infect Dis (2003) 5.55
Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis (2010) 5.53
Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis (2007) 5.51
Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother (2003) 5.48
Genome sequencing and analysis of Aspergillus oryzae. Nature (2005) 5.47
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis (2008) 5.39
Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med (2009) 5.27
The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis (2005) 5.25
Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis (2005) 5.24
Detection of four Plasmodium species in blood from humans by 18S rRNA gene subunit-based and species-specific real-time PCR assays. J Clin Microbiol (2004) 5.23
Trends in antimicrobial drug development: implications for the future. Clin Infect Dis (2004) 5.23
Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis (2007) 5.15
An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol (2008) 5.13
Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature (2005) 5.11
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant (2009) 5.10
Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis (2010) 4.98
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer (2010) 4.95
High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med (2009) 4.90
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis (2006) 4.88
Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis (2009) 4.71
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood (2008) 4.63
Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis (2012) 4.62
Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis (2009) 4.59
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med (2004) 4.56
Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis (2002) 4.56